
Two randomized phase III clinical trials targeting unresectable gastric and gastro-oesophagal junction carcinomas validate this observation. Thus, oxaliplatin-based chemotherapy favourably interacted with nivolumab, yielding an improved outcome. In contrast, the outcome of cisplatin-based chemotherapy failed to be improved by concomitant treatment with pembrolizumab. These clinical findings underscore the importance of choosing appropriate ICD-inducing cytotoxicants for developing chemoimmunotherapeutic regimens.
Like
Save
Share